Differences and efficacy differences between generic and original drugs of capmatinib

Capmatinib (Capmatinib) is a MET exon 14 skipping mutation (ME Tex14) tyrosine kinase inhibitor, mainly used to treat MET driven non-small cell lung cancer (NSCLC). Original drugs are developed by pharmaceutical companies and have been verified through rigorous clinical trials, with sufficient data to support their efficacy and safety. Generic drugs are equivalent drugs produced through chemical synthesis or process optimization based on the original drugs, aiming to reduce the cost of medication for patients while providing similar efficacy to the original drugs.

Original drugs and generic drugs are basically the same in active ingredients, but there may be differences in production processes, excipients and pharmaceutical preparations. The original drug has undergone multiple rounds of strict quality control and clinical verification, while the generic drug needs to pass a bioequivalence test to prove that it is basically consistent with the original drug in terms of blood concentration, absorption rate and body distribution. Although generic drugs are similar in ingredients, process differences between different manufacturers may result in slight differences in dissolution rates or stability.

Clinical studies have shown that generic drugs that have undergone strict supervision and bioequivalence verification are as effective as the original drugs in most patients. Both performed similarly in inhibiting tumor growth, prolonging progression-free survival (PFS), and improving quality of life. However, in some special patients or complex conditions, the original drug may still have certain therapeutic advantages or controllable side effects due to its complete clinical data and high drug stability.

When patients choose capmatinib, they should make individualized decisions based on their financial status, drug availability, and physician recommendations. For patients who cannot afford the high cost of original drugs, generic drugs from regular channels are a viable option, which can not only ensure the therapeutic effect, but also reduce the economic burden. During use, efficacy and adverse reactions should be closely monitored to ensure safety and effectiveness. At the same time, it is recommended to purchase through regular hospitals or pharmacies to avoid risks caused by informal channels.

Reference link:https://www.drugs.com